Expert Opinion on the Identification and Pharmacological Management of Worsening Heart Failure
Authors:
- Sandeep SethSSSandeep Seth
- Johann BauersachsJBJohann Bauersachs
- Sanjay MittalSMSanjay Mittal
- Vishal RastogiVRVishal Rastogi
- Rajeev Kumar RajputRRRajeev Kumar Rajput
- Dheeraj GandotraDGDheeraj Gandotra
- Ripen GuptaRGRipen Gupta
- Manoj SahuMSManoj Sahu
- S N PathakSPS N Pathak
- Mohit BhagwatiMBMohit Bhagwati
- Simmi MinochaSMSimmi Minocha
- Pawan SharmaPSPawan Sharma
- 1 January 2023
- journal article
- research article
- Published by Medknow in Journal of the Practice of Cardiovascular Sciences
- Vol. 9 (1) , 1-10
Abstract
Worsening heart failure (WHF) is a distinct under-diagnosed and under-treated condition, independent of location of care. Heart failure (HF) progression is punctuated by repeated WHF events, each resulting in reduced cardiac function. One-third of the patients with HF with reduced ejection fraction experience a decompensation event. These decompensation events often result in the emergency department visits and HF hospitalization. Despite its inclusion in recent guidelines, there is no precise definition of WHF or its various forms. It is worth noting that WHF signals a need for treatment optimization as per guideline-directed medical therapy and the addition of novel drugs like a stimulator of soluble guanylate cyclase that benefit this high-risk patient population. This practical document is based on the expert opinion of cardiologists, cardiothoracic surgeons, and physicians that discussed the definition, assessment, pharmacological management, and monitoring of WHF patients in a hospitalized setting. In addition, there is also a need for an expert opinion for the management of WHF in an outpatient setting.Keywords
This publication has 24 references indexed in Scilit:
- Worsening Heart Failure: Nomenclature, Epidemiology, and Future DirectionsJACC, 2023
- 2022 ACC/AHA/HFSA Guideline for the Management of Heart FailureJournal of Cardiac Failure, 2022
- Contextualizing Risk Among Patients With Heart FailureJAMA, 2021
- Five-year mortality and readmission rates in patients with heart failure in India: Results from the Trivandrum heart failure registryInternational Journal of Cardiology, 2021
- Diuretic Therapy for Patients With Heart FailureJACC, 2020
- Association of Change in N-Terminal Pro–B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection FractionJAMA, 2019
- Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection FractionJACC, 2019
- Efficacy of Sacubitril/Valsartan Relative to a Prior DecompensationJACC: Heart Failure, 2016
- Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection FractionJAMA, 2015
- Improving Care for Patients with Acute Heart Failure: Before, During and After HospitalizationESC Heart Failure, 2014